We construct a humanized mouse model of globoid cell leukodystrophy.
We inject recombinant human galactosylceramidase intravenously.
Enzyme is delivered across the blood–brain barrier to parenchymal brain cells.
Treatment reduces psychosine levels in the peripheral and central nervous system.
Enzyme replacement therapy has no effect on neuroinflammation and life span.